LLYEli Lilly and CompanyRunning, no new patients
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Sarcoma, Ewing · Neoplasm Metastasis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 46 (final count)
- Started
- Sep 20, 2022
- Main results expected
- Jan 15, 2025
- Fully finished
- Dec 2027
- Results posted
- Mar 12, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis
Measured over: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
PFS Assessed by BIRC by Frequentist Analysis
Measured over: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05440786 · record last updated 2026-10-20 · checked 2026-11-09 15:36 UTC